Highest-materiality recent filing
Biogen completes $5.3B acquisition of Apellis; stockholders get $41 cash + CVR up to $4
Tender offer accepted 105.7M shares (~82.4%); merger effective May 14, 2026.
Compensation committee approved amendment to Executive Separation Benefits Plan on April 28, 2026, in connection with Biogen merger.
Biogen to acquire Apellis for $41/share plus CVRs up to $4, total up to $45/share
Biogen to pay $41.00 per share cash upfront plus one CVR per share for Apellis (APLS).
Apellis adds Dr. Mikael Dolsten as independent Class I director
Dr. Mikael Dolsten elected to Apellis Board as Class I director effective March 1, 2026, serving until the 2027 annual meeting.
Full-year 2025 preliminary U.S. net product revenues: SYFOVRE $587M, EMPAVELI $102M, total $689M.
Apellis enters $275M royalty buy-down with Sobi; reduces Aspaveli royalties 90%
Sobi pays Apellis $275M upfront; up to $25M more on EMA approval of Aspaveli for C3G and IC-MPGN.
Elected A. Sinclair Dunlop (54.1M for, 26.0M withheld), Alec Machiels (62.3M for, 17.8M withheld), Keli Walbert (76.95M for, 3.18M withheld) as Class II directors for three-year terms.
Apellis appoints Craig A. Wheeler to Board, effective April 17, 2025
Craig A. Wheeler elected as Class III director; will serve until 2026 annual meeting.
Apellis reports $709M preliminary FY2024 U.S. net product revenue, COO Townsend to depart
Preliminary FY2024 U.S. net product revenues $709M; SYFOVRE $611M (120% YoY growth), EMPAVELI $98M.
Apellis/Sobi Phase 3 VALIANT meets primary endpoint; 68% proteinuria reduction in C3G/IC-MPGN
Statistically significant 68% proteinuria reduction vs placebo (p<0.0001) at Week 26.
Apellis stockholders elect directors, ratify auditor, approve executive pay at 2024 annual meeting
Paul Fonteyne elected with 98,837,712 votes for and 5,320,270 withheld; Stephanie Monaghan O'Brien elected with 80,481,023 for and 23,672,152 withheld.
Apellis closes $375M senior secured term loan; buys out SFJ Pharmaceuticals liability
Apellis entered $475M credit facility with Sixth Street; initial draw $375M; maturity May 2030 at SOFR+5.75% (1% floor).
Apellis FY2023 revenue $396.6M, SYFOVRE drives 160k+ doses; net loss $528.6M
Full year 2023 total revenue $396.6M (vs $75.4M in 2022); SYFOVRE $275.2M, EMPAVELI $91.0M.
Apellis appoints Adam Townsend as Chief Operating Officer, effective immediately
Adam Townsend, 47, previously Chief Commercial Officer since Nov 2018, assumes additional COO role.
Apellis reports preliminary Q4 2023 U.S. net product revenue of $138M, full year $366M
Q4 2023 U.S. net product revenue ~$138M: SYFOVRE $114M, EMPAVELI $24M.
CHMP negative trend vote on MAA for intravitreal pegcetacoplan for geographic atrophy (GA) after Dec 13 oral explanation.
Apellis updates SYFOVRE label to include rare retinal vasculitis risk; rate 0.01% per injection
Updated USPI Warnings/Precautions and Postmarketing Experience sections to include retinal vasculitis with/without occlusion.
Apellis enters $300M ATM offering with Cowen; prior Jefferies facility terminated
Entered Sales Agreement with Cowen to sell up to $300M of common stock via at-the-market offerings.
Mikael Dolsten, Paul Fonteyne, Stephanie Monaghan O’Brien, A. Sinclair Dunlop, Alec Machiels, Keli Walbert, Gerald Chan, Cedric Francois and Craig Wheeler each resigned from his or her respective position as a member of the Board of Directors of the Company and any committee thereof.
Mikael Dolsten, Paul Fonteyne, Stephanie Monaghan O’Brien, A. Sinclair Dunlop, Alec Machiels, Keli Walbert, Gerald Chan, Cedric Francois and Craig Wheeler each resigned from his or her respective position as a member of the Board of Directors of the Company and any committee thereof.
Mikael Dolsten, Paul Fonteyne, Stephanie Monaghan O’Brien, A. Sinclair Dunlop, Alec Machiels, Keli Walbert, Gerald Chan, Cedric Francois and Craig Wheeler each resigned from his or her respective position as a member of the Board of Directors of the Company and any committee thereof.
Mikael Dolsten, Paul Fonteyne, Stephanie Monaghan O’Brien, A. Sinclair Dunlop, Alec Machiels, Keli Walbert, Gerald Chan, Cedric Francois and Craig Wheeler each resigned from his or her respective position as a member of the Board of Directors of the Company and any committee thereof.
the director of Purchaser as of immediately prior to the Effective Time, Michael Dambach, became the director of the Company.
Mikael Dolsten, Paul Fonteyne, Stephanie Monaghan O’Brien, A. Sinclair Dunlop, Alec Machiels, Keli Walbert, Gerald Chan, Cedric Francois and Craig Wheeler each resigned from his or her respective position as a member of the Board of Directors of the Company and any committee thereof.
Mikael Dolsten, Paul Fonteyne, Stephanie Monaghan O’Brien, A. Sinclair Dunlop, Alec Machiels, Keli Walbert, Gerald Chan, Cedric Francois and Craig Wheeler each resigned from his or her respective position as a member of the Board of Directors of the Company and any committee thereof.
Mikael Dolsten, Paul Fonteyne, Stephanie Monaghan O’Brien, A. Sinclair Dunlop, Alec Machiels, Keli Walbert, Gerald Chan, Cedric Francois and Craig Wheeler each resigned from his or her respective position as a member of the Board of Directors of the Company and any committee thereof.
Mikael Dolsten, Paul Fonteyne, Stephanie Monaghan O’Brien, A. Sinclair Dunlop, Alec Machiels, Keli Walbert, Gerald Chan, Cedric Francois and Craig Wheeler each resigned from his or her respective position as a member of the Board of Directors of the Company and any committee thereof.
Mikael Dolsten, Paul Fonteyne, Stephanie Monaghan O’Brien, A. Sinclair Dunlop, Alec Machiels, Keli Walbert, Gerald Chan, Cedric Francois and Craig Wheeler each resigned from his or her respective position as a member of the Board of Directors of the Company and any committee thereof.
On April 17, 2025, the Board of Directors (the “Board”) of Apellis Pharmaceuticals, Inc. (the “Company”), upon recommendation from the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”), elected Craig A. Wheeler to the Board as a Class III director to serve until the Annual Meeting of Stockholders to be held in 2026 or until his successor has been duly elected and qualified or until his earlier death, resignation or removal.
On January 10, 2025, the Company and Adam Townsend mutually agreed that Mr. Townsend will resign as the Company’s Chief Operating Officer effective as of February 21, 2025 (the “Separation Date”).
Max materiality 1.00 · Median 0.75 · Most common event other_material